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httpcense.Abstract Objectives: Exudative pleural effusion represents a common diagnostic task to the clini-
cian. The two commonest causes of exudative pleural effusion are parapneumonic followed by
malignant ones. However, obtaining a deﬁnite diagnosis is essential for proper management of
the effusion. The aim of this work was to evaluate the role of the ﬁberoptic bronchoscope used
as a thoracoscope in management of exudative pleural effusion.
Patients and methods: Eighty-four patients with exudative pleural effusion of undetermined eti-
ology were enrolled in this study. All patients were subjected to full history taking, thorough clinical
examination, pleural ﬂuid aspiration and analysis, computed tomography of the chest and ultra-
sound examination of the pleural cavity. Under conscious sedation and local anaesthesia, ﬁberoptic
thoracoscopy was then carried out using ﬁberoptic bronchoscope inserted through a rigid large sil-
iconized chest tube. After drainage of the pleural ﬂuid, the pleural cavity was carefully explored and
multiple forceps biopsies were taken and sent for histopathological examination. Pleurodesis was
then done using iodopovidone in patients with apparent pleural pathology. After lung expansion
and pleural ﬂuid drainage of less than 100 cc/day, the chest tube was removed.
Results: Successful histopathological diagnosis was achieved in all patients. It revealed that 63
(75%) cases had malignant pathology and 21 (25%) cases had inﬂammatory pathology. The malig-
nant pathology was caused by: bronchogenic carcinoma in 28 (33.3%) cases, malignant mesotheli-
oma in 2 (2.38%) cases and metastatic malignant deposits from other organs in 33 (39.28%) cases.
The inﬂammatory pathology was tuberculosis in 16 (19%) cases and non-speciﬁc pleurisy in 5
(5.95%) cases. Pleurodesis was performed and was successful in all the patients. Two (2.38%)
patients developed empyema after the procedure and they were successfully managed by intercostal7973726.
om (T.S. Morsi).
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406 M.A. Atta et al.tube drainage and anitibiotic therapy. Other complications encountered included local wound infec-
tion in 3 (3.57%) cases, subcutaneous emphysema in 3 (3.57%) cases and chest pain following pleu-
rodesis in 15 (17.85%) cases.
Conclusion: Thoracoscopy using the ﬁbroptic bronchoscope is safe and effective. It is an alter-
native technique to rigid thoracoscopy with some advantages as it allows better exploration of
the pleura. It is equally as efﬁcient as the rigid thoracoscope and hardly more time consuming. With
proper handling, there will not be any damage or abuse of the ﬁbroptic bronchoscope.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
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Pleural effusion evolves in the course of a variety of diseases. It
represents a common diagnostic task to the clinician. A correct
diagnosis of the underlying disease is essential to the rational
management. In some cases, a diagnosis may be established
without difﬁculty. However, despite employment of extensive
diagnostic procedures, the cause used to be described as
remaining elusive in about 10% of all cases [1].
Pleural effusion is classiﬁed into transudate and exudates
based on the criteria established by Light [2]. The accuracy of
these criteria is very high; however, other authors found poorer
diagnostic results when applying Light0s criteria, which may
lead to further unwarranted invasive interventions in up to
10–36% of patients with transudates especially after receiving
diuretics [3]. The serum serum-pleural albumin gradient can dif-
ferentiate exudative from pseudo-exudative pleural effusion in
such patients. A gradient of pleural ﬂuid to serum albumin
P1.2 g/dL identiﬁes a transudative pleural effusion [4].
The commonest cause of exudative pleural effusion is
parapneumonic followed by malignant effusions. Although
parapneumonic effusions are commoner, they are usually
small and resolve by medical treatment without any invasive
intervention [5]. Hence, malignancy is probably the leading
cause of exudative effusion subjected to thoracentesis [6].
Nearly all neoplasms have been reported to involve the pleura;
however, carcinomas of the lung followed by that of the breast
are by far the commonest causes. In approximately 6% of pa-
tients with malignant pleural effusions, the primary tumor is
not identiﬁed [7].
Attempts to obtain a diagnosis for a pleural effusion usu-
ally involve ﬂuid aspiration and analysis and biopsy specimens
of the pleura by closed needle biopsy. The yield of such proce-
dures is not often satisfactory. The diagnostic yield of a biopsy
performed under thoracoscopic vision is often superior. Tho-
racoscopy, with high quality image, magniﬁcation and total
visualization of the pleural cavity enables a thorough inven-
tory of the thoracic cavity to be carried out [8].
There are few contraindications to thoracoscopy. Most
operators agree that the procedure should be avoided if a pleu-
ral space sufﬁcient for visualization and mobilization of the
instrumentations is not obtained, patients with severe coagul-
opathies and very stiff lung which cannot be effectively col-
lapsed. Relative contraindications include honeycomb lung,
suspected arterio-venous malformations, highly vascular pul-
monary lesions and empyema that cannot be effectively
drained using thoracoscopy [9].
The aim of this work was to evaluate the role of the ﬁber-
optic bronchoscope used as a thoracoscope in management of
exudative pleural effusion.Patients and methods
Patients included in this study were seen in the respiratory
medicine department of the main teaching hospital of Alexan-
dria University, Egypt. The present study included 84 patients
with exudative pleural effusion of undetermined etiology fol-
lowing biochemical, bacteriological and cytological analysis
of the pleural ﬂuid. The amount of the pleural ﬂuid was esti-
mated to be more than 500 cc. All patients had a prothrombin
activity >70%.
All patients were subjected to full history taking, thorough
clinical examination and venous blood sample for complete
blood picture, renal and liver function tests, fasting blood glu-
cose level, prothrombin activity, total serum protein, albumin
and lactate dehydrogenase content. The pleural ﬂuid was aspi-
rated and analyzed for its total protein and albumin content,
lactate dehydrogenase content [LDH], total and differential
leucocytic count, Ziehl-Neelsen stain for acid fast bacilli and
cytological examination for malignant cells. The followings
were then calculated: (1) pleural ﬂuid protein/serum protein ra-
tio, (2) pleural ﬂuid LDH/serum LDH ratio and (3) pleural
serum albumin gradient.
Radiological evaluation was carried out by plain X-ray
chest postero-anterior view and computed tomography (CT)
scan of the chest with focus made on the side and amount of
effusion, pleural lesions, underlying lung lesions, metastasis
and any other lesions that could be detected. Finally, ultra-
sound examination of the pleural cavity was often done just
before the thoracoscopy procedure to ensure an adequate
dependent space for best drainage of pleural ﬂuid while avoid-
ing lung injury. It also allowed detection of pleural adhesions
and multi-loculated effusion.
Fiberoptic thoracoscopy was then carried out using ﬁber-
optic bronchoscopy [PENTAX, ﬁberoptic bronchoscopy] and
videoscopy unit (camera [KARL STORZ ENDOSKOPE
TELECAM PAL 20211020], light source [HENKE-SASS
WOLF GMBH D-7200 TUTTINGEN)], video recorder and
television. The patient was positioned lying down in a lateral
decubitus position with the involved side facing upwards.
The entire lateral chest wall was scrubbed with iodopovidone
for disinfection. Exploratory thoracentesis to conﬁrm the pres-
ence of pleural ﬂuid at the insertion site was done before inser-
tion of the tube.
Conscious sedation with propofol was carried out with
loading doses of 0.2–0.5 mg/kg and maintenance dosages of
0.5–4 mg/kg/h.
The skin, subcutaneous tissues, muscle planes, rib perios-
teum and parietal pleura were anesthetized by about 30 cc of
1% lidocaine. A 2 cm transverse skin incision was made by a
scalpel parallel to the rib along the intercostal space chosen
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was performed by straight Kelly clamp and the parietal pleura
was gently palpated by the index ﬁnger and then was pene-
trated by the Kelly clamp. A rigid siliconized chest tube sized
40F (Fig. 1) was grasped with a large Kelly clamp and inserted
through the incision, down the preformed tract, penetrating
the pleural membrane into the pleural cavity. A suction cathe-
ter was then inserted in the tube and all the pleural ﬂuid
drained. From time to time, the suction was stopped and the
outer tip of the chest tube was left open to ensure entry of
air replacing the drained ﬂuid to avoid re-expansion pulmon-
ary edema. This also helped maintaining the lung collapsed,
facilitating the procedure.
After drainage of the ﬂuid, the ﬁberoptic bronchoscope was
introduced through the ﬁrm wide bore chest tube into the pleu-
ral space. After aspiration of the pleural ﬂuid, the distal end of
the silicone intercostal tube was sometimes blocked by the par-
tially expanding lung. This event necessitated partial with-
drawal of the intercostal tube, which was done under
ﬁbroptic bronchoscope vision in order not to withdraw the
tube completely out of the pleural space. The bronchoscope
was then connected to a video camera in order to display the
whole procedure on a monitor and can be recorded on a video
tape by a video recorder. Suction of any remaining part of the
pleural ﬂuid was done through the suction channel of the bron-
choscope. The total amount of the drained pleural ﬂuid was
estimated. Inspection of the pleural cavity was then done by
the ﬁberoptic bronchoscope. The parietal pleura including
the costal, diaphragmatic sometimes mediastinal pleura as well
as the visceral pleura were thoroughly examined for any le-
sions such as nodules, plaques, adhesions, thickening, mottling
or anthracosis. Multiple forceps biopsies were taken from any
suspicious gross pathological lesion in the parietal pleura. The
visceral pleura was not biopsied. The biopsies were taken by
the forceps which was passed through the side channel of the
bronchoscope. The biopsies were then sent for histopatholo-
gical diagnosis.
After the procedure the chest tube was connected to the
drainage device [HOSPIVAC sm350 REF210358] and ﬁxed
in position to the skin of the chest wall using two-zero proline
interrupted vertical mattress sutures. Well cared dressing was
applied. The dressing was routinely changed and inspected dai-
ly. Daily plain X-ray chest was done to verify that the lung has
fully expanded. Then when the pleural ﬂuid drained was lessFigure 1 The rigid siliconized intercostal chest tube (40F).than 100 cc/day, pleurodesis was performed. The chest tube
was ﬁrst clamped with two clamps and was disconnected from
the suction tube of the draining device. Twenty cubic centime-
ter of lidocaine (1% concentration) were instilled into the pleu-
ral cavity through the chest tube to anesthetize the pleura.
Under strict aseptic technique, 50 cubic centimeter of iodop-
ovidone (10% concentration) were added to 50 cubic centime-
ter normal saline in a sterile bowl and aspirated into the 50
cubic centimeter Tommy0s syringe. The syringe was attached
to the chest tube and the solution was instilled through the
chest tube after both clamps have been removed, then the
remaining 50 cubic centimeter of the solution were instilled
in the same manner. This technique was adopted in the ﬁrst
forty cases. However, in the later cases, the iodopovidone
introduction was done during the thoracoscopic procedure fol-
lowing the pleural biopsies and after adequate suction.
Chest radiograph was done daily to assure full lung re-
expansion. Once this latter was achieved and the pleural ﬂuid
drained was less than 100 cc/day, the chest tube was removed.
After removing the chest tube, a plain chest radiograph was
obtained. Close observation for any complication was carried
out and recorded. The complications were then managed.Results
The mean age of the patients was 55.36 ± 15.75 years with a
maximum of 83 and a minimum of 17 years. There were 52
male and 32 female patients. Thirty-six patients (45%) were
smokers and they were all males. All the patients were symp-
tomatic at the time of referral. The presenting symptoms were
dyspnea in 80 patients (95%), chest pain in 55 patients
(65.4%), cough in 44 (52.4%) patients and loss of weight in
44 (52.4%) patients.
The mean serum protein of the studied patients was
6.71 ± 0.48 g/dL with a maximum of 7.7 and a minimum of
5.4 g/dL; while the mean serum albumin was 3.8 ± 0.38 g/dL
with a maximum of 4.8 and a minimum of 3.2 g/dL. The mean
serum lactate dehydrogenase (LDH) was 615.85 ± 369.09 IU/
L with a maximum of 1650 and a minimum of 389 IU/L.
Computed tomography of the chest detected, in addition to
pleural effusion, thickened pleura in 50 patients (59.52%), en-
cysted effusion in 5 (5.95%) patients, pulmonary soft tissue
shadows in 5 (5.95%) patients and mediastinal lymphadenop-
athy in 4 (4.76%) patients.
The mean pleural total WBCs was 3647.52 ± 1564.56 cells/
cmm with a maximum of 7000 and a minimum of 1040 cells/
cmm. The mean pleural total protein was 4.51 ± 0.49 g/dL
with a maximum of 6.1 and a minimum of 3.7 g/dL. The mean
pleural/serum protein ratio was 0.67 ± 0.08 with a maximum
of 0.81 and a minimum of 0.55. The mean pleural albumin
was 3.41 ± 0.29 g/dL with a maximum of 4.1 and a minimum
of 2.9 g/dL. The mean pleural-serum albumin gradient was
0.51 ± 0.21 g/dL with a maximum of 0.9 and a minimum of
0.19 g/dL. The mean pleural lactate dehydrogenase (LDH)
was 523.96 ± 331.11 IU/L with a maximum of 2222 and a
minimum of 300 IU/L. The mean pleural/serum LDH ratio
was 0.86 ± 0.07 with a maximum of 0.95 and a minimum of
0.71. The mean pleural glucose was 67.32 ± 24.12 mg/dL with
a maximum of 195 and a minimum of 45 mg/dL. The pleural
ﬂuid culture was sterile in all patients. Zeihl-Nelseen staining
of pleural ﬂuid for acid fast bacilli (AFB) was negative in all
Figure 2 Multiple parietal pleural nodules.
Figure 3 Pleural thickening and adhesions.
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cells was positive in only one patient (1.19%); however it
was not diagnostic to the underlying primary tumors. (Table 1)
The mean amount of pleural ﬂuid drained was 3.82 ± 2.56
liters with a maximum of 8 and a minimum of 0.75 liters. The
visceral pleura was affected in 80 (95.2%) patients. The parie-
tal pleura was affected in all patients; with costal affection in
80 (95.2%) patients and diaphragmatic affection in 20
(23.8%) patients. Pleural thickening (Fig. 3) was traced in 22
(26.2%) patients, nodules (Fig. 2) in 68 (80.9%) patients, pla-
ques in 7 (8.3%) patients, adhesions (Fig. 3) in 32 (38.09%) pa-
tients, anthracosis in 13 (15.47%) patients, and mottling in 11
(13.09%) patients. (Table 2)
The histopathological diagnosis of the pleural biopsy re-
vealed that 63 (75%) cases had malignant pathology and 21
(25%) cases had inﬂammatory pathology. The malignant
pathology was caused by: bronchogenic carcinoma in 28
(33.3%) cases, malignant mesothelioma in 2 (2.38%) cases
and metastatic malignant deposits from other organs in 33
(39.28%) cases. (Table 3) The inﬂammatory pathology was
tuberculosis in 16 (19%) cases and non-speciﬁc pleurisy in 5
(5.95%) cases. Those latters received non-speciﬁc antibiotic
therapy and the follow up for 6 months revealed full cure with
no recurrent effusion.
Pleurodesis using iodopovidone was performed initially in
all patients except 2 (2.38%), as they developed empyema after
the procedure. Pleurodesis was successful in all the patients;
and the mean time needed to achieve complete lung expansion
was 2 days, varying from 1 to 4 days. Regarding the 2 patients
who developed empyema, they were successfully managed by
intercostal tube drainage and anitibiotic therapy. One case re-
solved after 2 weeks; however the empyema persisted for
3 months in the other case before complete resolution. In those
two cases, empyema developed following initial failure of lung
expansion. Pleurodesis was then done successfully in both
cases. Overall, the initial success rate of pleurodesis (after
1 week) following iodopovidone introduction was 100%.
Other complications encountered were minimal and in-
cluded local wound infection in 3 (3.57%) cases; it was man-
aged by local antibiotics and local antiseptics and all
resolved within 4–5 days. Subcutaneous emphysema was
encountered in 3 (3.57%) cases and resolved spontaneously
within one or two days after the procedure. Chest pain follow-
ing iodopovidone instillation in the pleural cavity was encoun-
tered in 15 (17.85%) cases.
Discussion
Thoracoscopy was introduced by Jacobaeus in 1910, primarily
to diagnose pleural effusion using cystoscope [10]. However,
the French term of thoracoscopy: ‘‘thoracoscopie’’ was well
known long before Jacobaeus [11]. Nowadays, the most com-Table 1 Pleural ﬂuid analysis results and ratios of the studied pati
Proteins (g/dL) P/S proteins Albumin (g/dL) P
Mean 4.51 0.67 3.41 0
SD 0.49 0.08 0.29 0
SD: standard deviation, g/dL: gram/deciliter, P/S: pleural to serum ratio
international unit/liter, mg/dL: milligram/decilitermon indications for thoracoscopy include evaluation of the un-
known exudative effusion, management of malignant
mesothelioma or lung cancer, and treatment of other recurrent
effusions or empyema. Other less common indications include
treatment of spontaneous pneumothorax, taking biopsies from
the diaphragm, lung, mediastinum and pericardium, resection
of small peripheral lung lesions, sympathectomy for palmar
and axillary hyperhydrosis, resection of mediastinal masses
and treatment of resistant pericardial effusion [12].
Medical thoracoscopy can be done under general or local
anaesthesia as stated by the European Respiratory societyents.
–S Albumin LDH (IU/L) P/S LDH Glucose (mg/dL)
.51 523.96 0.86 67.32
.21 331.11 0.07 24.12
, P–S: pleural–serum gradient, LDH: lactate dehydrogenase, IU/L:
Table 2 Thoracoscopic ﬁndings of pleural affections in the studied patients.
Visceral Parietal Type of the lesions
Costal Diaphragmatic Thickening Odules Plaques Adhesions
Number 80 80 20 22 68 7 32
Percent 95.2 95.2 23.8 26.2 80.9 8.3 38.09
Table 3 Histopathological diagnosis of pleural biopsy in the
studied patients.
Number Percent
Bronchogenic carcinoma
Small cell lung cancer 6 7.1
Non-small cell lung cancer 22 26.19
Malignant mesothelioma 2 2.38
Metastatic carcinoma
Breast 13 15.47
Thyroid 5 5.95
Endometrial 4 4.8
Renal cell 3 3.57
Colon 6 7.1
Unknown primary 2 2.38
Inﬂammatory
Tuberculous 16 19
Non-speciﬁc 5 5.95
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patient, as well as on the experience of the physician and insti-
tutional biases. In the current study, we preferred to use local
anaesthesia with conscious sedation as it is safer and associ-
ated with fewer complications than general anaesthesia [14].
Also, general condition and comorbidities of some patients
with massive effusion would not allow the use of general
anaesthesia.
In the present study, the wide ﬁrm silicone chest tube which
was inserted prior to the procedure aimed at protecting the ﬁ-
bres of the bronchoscope during the procedure. The usual tro-
car of the thoracoscope is more traumatizing to the ﬁbres of
the bronchoscope due to friction against its solid body and
rim. Previous investigators were so concerned about such a
hazard of damaging the ﬁbres of the bronchoscope, that they
went up to the point of ensheathing the ﬂexible bronchoscope
with a close siliconised polyvinyl tube, which was then passed
through a standard trocar [15].
Re-expansion pulmonary oedema is a well described but
rare complication following rapid expansion of a collapsed
lung through evacuation of large amounts of pleural ﬂuid at
a single time and the use of early and excessive pleural suction
[16]. In this study, drainage of several liters (up to 8 liters in
one case) of pleural ﬂuid was done in one session, there no
cases of re-expansion pulmonary oedema though. This was
possible by immediate equilibration of pressure secondary to
direct entrance of air through the intercostal tube into the
pleural space from around the draining catheter and the ﬁbr-
optic bronchoscope during the procedure. The reported inci-
dence of re-expansion pulmonary oedema in previous studies
varied from 0% [17] to up to 14.38% [18]. In a large previous
study, 12 patients (2.2%) developed reexpansion pulmonary
edema during thoracoscopy. The total ﬂuid drained in thosepatients was always >3000 L (range: 3200–5000 L). They rec-
ommended performing one or two therapeutic thoracenteses
before thoracoscopy, with the drainage of at least 1500 L at
each procedure for patients with large pleural effusions. [19]
We found such recommendation not necessary.
In the present study, in some cases the visualization by the
bronchoscope was difﬁcult upon its initial introduction
through the chest tube into the pleural space due to the pres-
ence of excess pleural ﬂuid. This was not troublesome as it
was solved by direct suctioning of the remaining part of the
ﬂuid by the bronchoscope. In rigid thoracoscopy however,
when the same condition was encountered, the operator must
remove the thoracoscope, introduce an aspiration catheter to
attempt suctioning the remaining ﬂuid [20]. Such procedure
could be repeated several times as the suction is done blindly
and could be time consuming. In some cases, we were actually
lost in the pleural space. It was not much troublesome. The
simple act of withdrawal of the ﬁbroptic bronchoscope till
the tip of the intercostals tube resolved the matter; and then
further examination of the pleura was carried out. Using the
ﬁberoptic bronchoscope, it was easy to visualize the whole
parts of the costal pleura. We had a very good access to the
apical pleura and the costal one around the site of entery of
the intercostal tube. Such areas are difﬁcult if not sometimes
impossible to be visualized by rigid thoracoscopy. Such obser-
vations have been reported before [15].
While attempting to take a pleural biopsy, slipping of the
pleura from the ﬁbroptic bronchoscope foreceps occurred in
some cases. The grip of the foreceps of the ﬁbroptic broncho-
scope is less adequate than that of the rigid thoracoscope as it
is much smaller. In order to obtain adequate sufﬁcient biopsies
and to overcome this problem the bronchoscope was bended,
so that the forceps was at 90 angle to the pleura to prevent
the forceps from slipping and it was gently rubbed against
the pleural surface prior to biopsy taking. By this technique
proper biopsies were taken in all our cases. The size of the
forceps biopsy was small and to compensate for that several
biopsies were taken to ensure adequate histopathological
diagnosis. The use of crocodile foreceps, which has longer
and sharper cutting blades, in some of our cases, had more
favorable results as larger biopsies were obtained. Previous
studies reported failure to obtain adequate pleural biopsy by
the same technique and recommended the use of larger rigid
thoracoscopic biopsies [15]. However, we achieved histopa-
thological diagnosis in all our cases; mostly due to obtaining
multiple biopsies and meticulous histopathological prepara-
tion and examination.
We did not use suction routinely after thoracoscopy. Suc-
tion was required for incomplete lung expansion in 21 cases
following the procedure. When suction is applied, the use of
high volume, low pressure systems is recommended with a
gradual increment in pressure to about 20 cm H2O. The Brit-
ish Thoracic Society guidelines for the insertion of a chest
410 M.A. Atta et al.drain stated that suction (high volume, low pressure systems) is
to be applied to the chest tube only when needed and even if
applied it is acceptable to stop suction for short period pro-
vided that the underwater seal bottle is kept below the level
of the chest [21].
In the present study, we found that gross thoracoscopic
appearances coincided well with the deﬁnite histological diag-
nosis. The presence of nodules mostly indicates malignancy,
while diffuse thickening, adhesions and plaques suggest tuber-
culous or other inﬂammatory pleural affections. This observa-
tion was previously reported in large series of studies [22,23],
however, others reported it as unreliable [24,25]. We deﬁnitely
recommend histopathological proof for proper diagnosis of
the pleural pathology. All our cases were biopsied successfully
inspite of the presence of adhesions in many of them in which
obtaining biopsies was difﬁcult and time consuming. Previous
studies reported failure to reach diagnosis in a limited number
of patients due to extensive pleural adhesions [15,26,27]. In our
study, histopathological diagnosis was achieved in all cases.
Pleurodesis is induction of permanent adhesion of visceral
and partietal pleural surfaces by chemical, mineral or mechan-
ical methods in order to prevent the recurrence of pleural
effusion or pneumothorax and to improve the quality of life
[26–28]. The mechanism of pleurodesis is based on pleural
irritation to create an inﬂammatory reaction which stimulates
ﬁbrosis. However, the exact mechanism and factors governing
the outcome of pleurodesis are not well known [29–34]. It is
frequently employed world-wide in the management of malig-
nant pleural effusions. In the United States alone, an estimated
100.000 patients undergo pleurodesis each year [35]. Despite
the wide spread application of pleurodesis, little is known
regarding the optimal method for performing the procedure
[35]. Few clinical trials have been conducted to establish the
preferred pleurodesis agent or the best technique for inducing
pleurodesis. Consequently, practice guidelines puplished by
international professional societies were mainly based on
expert consensus [36].
Previous studies reported that performing pleurodesis
through thoracoscopy under vision may be better than being
done blindly through tube thoracostomy; assuring a uniform
distribution of the sclerosing agent [30,36]. Also, during
thoracoscopy any loculated ﬂuid or pleural adhesions can be
eliminated ensuring adequate drainage of all pleural ﬂuid
and better apposition of the parietal and visceral pleurae
[37]; however this could be done and still, the instillation of
the sclerosing agent performed later [35,36]. In the present
study, pleurodesis was performed in all our cases as there were
apparent pleural affections in all of them. Initially, pleurodesis
was done few days after thoracoscopy to ensure full drainage
of the pleural ﬂuid and complete lung expansion before per-
forming this maneuver. This technique was adopted in previ-
ous studies and for the same reasons previously mentioned
[38]. However, later on, we adopted the other technique more
practiced nowadays which is to perform pleurodesis at the end
of the thoracoscopic procedure under vision. This was more
convenient to the patient. There was no difference in the
successful outcome of both technique, although, adopting
the latter technique seemed to shorten slightly the hospital stay
of the patient.
The sclerosing agent used in the present study was iodop-
ovidone. The initial success rate of pleurodesis (after one week)
using this substance was 100%. Various substances have beenused to induce pleurodesis in the previous decades. While
reading previous reports we came across more than 35 agents
[29–34,39]; and we were not particularly looking for them.
However none of them meets the characteristics of an ideal
sclerosing agent which should be of low cost, widely available,
easy to handle and administer, easy to sterilize, does not induce
infection, discomfort nor pain and with 100% efﬁcacy [39].
Iodopovidone is a topical antiseptic that has been shown to
be safe and effective sclerosing agent in several studies
[38,40,41]. The precise mechanism of action of iodopovidone
remains unclear, but it leads to enhanced pleural ﬁbrosis which
may be related to its low pH (2.97), or to the strong oxidative
and cytotoxic properties of iodine that can induce a potent
inﬂammatory response [40,41]. A survey conducted among
pulmonologists about pleurodesis practice for malignant pleu-
ral effusion, reported that the most effective sclerosing agent
was talc [28,35]. The reported incidence and types of adverse
effects of different sclerosing agents are variable in different
previous studies [29–34,39]. Studies showed that talc pleurod-
esis was associated with signiﬁcantly more side effects than
the other agents, such as fever, pain, nausea, transient
hypotension and atrial arrhythmia. Laboratory evidence has
demonstrated that talc induces signiﬁcant release of
pro-inﬂammatory cytokines, which although contributing to
its success, could lead also to serious side effects. Granuloma-
tous pneumonitis, brain microembolization, ARDS, respira-
tory failure and even deaths have been reported in several
series following the use of talc as a pleurodesis agent irrespec-
tive of doses and route of administration. A sizeable number of
pulmonologists, irrespective of their preferred agents, reported
that they have observed death as a complication of pleurodesis
[42,43]. These data highlight that pleurodesis is not entirely
benign. It carries deﬁnite, though uncommon, risks of serious
complications. There is an urgent need to reﬁne current agents
or to develop new ones with a better efﬁcacy and safety proﬁle
[28].
Apart from the two cases of empyema encountered, the
other complications were minimal and easily controlled. The
incidence of complications in previous studies, whether using
ﬂexible ﬁbroptic thoracoscopy or rigid thoracoscopy
[14,20,25–27,44] was markedly variable. It is difﬁcult to
summarize the overall complication rate because it depends
on the indication of thoracoscopy, type of anaesthesia, equip-
ment used, patient population, experience of the operator and
adequacy of post procedure care [14]. Some complications are
considered trivial that many operators would not bother to
report them. These factors can explain the wide range of
variation in the reported incidence of post-thoracoscopic
complications.
Thoracoscopy is a safe and effective procedure, either as a
diagnostic or therapeutic one. Our experience with ﬁbroptic
bronchoscope used as a thoracoscope proved equally safe
and effective. We are not suggesting that this technique should
replace the traditional thoracoscopy, but it is a good alterna-
tive technique. It has even some advantages over the rigid
thoracoscope. Being ﬂexible, the bronchoscope allows a better
exploration of both the visceral and the parietal pleura and
safely reaching even the mediastinum. It would also be associ-
ated with less traumatic risk than the rigid thoracoscope. The
presence of the suction channel in the bronchoscope allows
better and easier drainage of all the pleural ﬂuid. We have
probably emphasized on the smaller forceps biopsy of the
Fiberoptic thoracoscopy in management of exudative pleural effusion 411bronchoscope, hence the need of a larger number of biopsies,
being time consuming. However, the sparing of general
anesthesia gained more time and overall, the procedure hardly
took more time than that with the rigid thoracoscope. With
proper handling, there will not be any damage or abuse of
the ﬁbroptic bronchoscope. The abuse of the instrument
would occur because of the operator‘s handling and not the
procedure itself.
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